Screener
iRadimed IRMD G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of revenue | 5,165 | 4,668 |
| Gross profit | 16,814 | 14,843 |
| Operating expenses: | ||
| General and administrative | 4,569 | 4,611 |
| Sales and marketing | 4,052 | 4,176 |
| Research and development | 956 | 624 |
| Total operating expenses | 9,577 | 9,411 |
| Income from operations | 7,237 | 5,432 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's G&A?
- iRadimed (IRMD) reported G&A of $4.57M in Q1 2026.
- How has iRadimed's G&A changed year-over-year?
- iRadimed's G&A decreased by 0.9% year-over-year, from $4.61M to $4.57M.
- What is the long-term trend for iRadimed's G&A?
- Over 4 years (2021 to 2025), iRadimed's G&A has grown at a 16.1% compound annual growth rate (CAGR), from $9.77M to $17.78M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about iRadimed's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude